Subsequently, the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm revealed that the response to ICIs was poorer in the high BTBD10 expression group than in the low BTBD10 expression group (high TIDE score, worse response to ICIs, and short survival after ICIs treatment) (Jiang et al., 2018a) (Figure 7C). This evidence concerns the gene BTBD10 and neoplasm.